GSG Advisors’s CorMedix CRMD Stock Holding History

GSG Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$126K	Hold	16,000	–	–	0.03%	147
2026 Q1	$109K	Hold	16,000	–	–	0.03%	136
2025 Q4	$186K	Hold	16,000	–	–	0.05%	133
2025 Q3	$177K	Hold	16,000	–	–	0.05%	125
2025 Q2	$197K	Sell	16,000 -6,000	-27%	-$66.2K	0.06%	118
2025 Q1	$154K	Sell	22,000 -4,500	-17%	-$46.6K	0.05%	111
2024 Q4	$215K	Sell	26,500 -11,000	-29%	-$110K	0.07%	105
2024 Q3	$304K	Hold	37,500	–	–	0.1%	93
2024 Q2	$161K	Hold	37,500	–	–	0.06%	104
2024 Q1	$155K	Sell	37,500 -12,000	-24%	-$41.6K	0.06%	103
2023 Q4	$177K	Buy	49,500 +19,500	+65%	+$67.1K	0.07%	106
2023 Q3	$111K	Buy	+30,000	New	+$119K	0.05%	82

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GSG Advisors's CRMD Position: Q2 2026 in Review

GSG Advisors held its CorMedix (CRMD) position steady in Q2 2026 at 16,000 shares worth $126K. The position accounts for 0.03% of the portfolio, ranked #147.

GSG Advisors first reported a position in CRMD in Q3 2023 and has held it in 12 quarters since. The position peaked at $304K in Q3 2024. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

GSG Advisors held 16,000 shares of CorMedix worth $126K as of Q2 2026.
GSG Advisors left its CorMedix share count unchanged in Q2 2026.
CorMedix made up 0.03% of GSG Advisors's portfolio in Q2 2026, its #147 holding.
GSG Advisors first reported a position in CorMedix in Q3 2023 and has held it in 12 quarters since.
GSG Advisors's CorMedix position peaked at $304K in Q3 2024.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on GSG Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.